XVIVO: The European heart launch is delayed for 6-12 months - Redeye

The delayed launch is a setback for both XVIVO, patients and specialist centers waiting to use the solution. The remaining CE approval clearance relates to the perfusion solution. We look forward to a more detailed timetable at the Q3 report in October.

Länk till analysen i sin helhet: https://www.redeye.se/research/1121170/xvivo-the-european-heart-launch-is-delayed-for-6-12-months?utm_source=finwire&utm_medium=RSS